Original Research
Published on 04 Sep 2024
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)
in Cancer Immunity and Immunotherapy
- 271 views